https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-11-01 / Cancer Immunol. Immunother. 2018 02;67(2):285-298
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-11-01 / Cancer Immunol. Immunother. 2018 02;67(2):285-2982017-11-01 00:00:002019-02-15 08:49:51A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-10-01 / Ann Transl Med 2017 Oct;5(19):386
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-10-01 / Ann Transl Med 2017 Oct;5(19):3862017-10-01 00:00:002019-02-15 08:49:52Dendritic cell therapy in melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-08-01 / Melanoma Res 2017 08;27(4):351-357
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-08-01 / Melanoma Res 2017 08;27(4):351-3572017-08-01 00:00:002017-08-01 00:00:00Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-27 / Oncotarget 2017 Sep;8(40):67439-67456
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-27 / Oncotarget 2017 Sep;8(40):67439-674562017-06-27 00:00:002017-06-27 00:00:00Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-20 / JCI Insight 2017 Apr;2(8)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-20 / JCI Insight 2017 Apr;2(8)2017-04-20 00:00:002019-02-15 08:49:48Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-11-29 / Melanoma Manag 2016 Dec;3(4):273-289
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-11-29 / Melanoma Manag 2016 Dec;3(4):273-2892016-11-29 00:00:002016-11-29 00:00:00Dendritic cell vaccines for melanoma: past, present and future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-10-18 / Oncoimmunology 2016;5(11):e1232237
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-10-18 / Oncoimmunology 2016;5(11):e12322372016-10-18 00:00:002019-02-15 08:49:47Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-29 / Ophthalmology 2016 10;123(10):2265-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-29 / Ophthalmology 2016 10;123(10):2265-72016-07-29 00:00:002019-02-15 08:49:46Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-18 / Case Rep Med 2016;2016:9639585
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-18 / Case Rep Med 2016;2016:96395852016-07-18 00:00:002019-02-15 08:49:45Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-20 / Hum Vaccin Immunother 2016 10;12(10):2523-2528
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-20 / Hum Vaccin Immunother 2016 10;12(10):2523-25282016-06-20 00:00:002019-02-15 08:49:43Dendritic cell vaccination in melanoma patients: From promising results to future perspectives
